docetaxel + indoximod + paclitaxel

This is a combination regimen consisting of three agents: - **Docetaxel** is a taxane-class antineoplastic agent that promotes microtubule assembly and inhibits their disassembly, leading to cell cycle arrest and apoptosis. It is widely used in the treatment of breast, lung, prostate, gastric, and head/neck cancers. - **Paclitaxel** is another taxane antineoplastic agent with a similar mechanism—stabilizing microtubules to inhibit mitosis. It is approved for ovarian, breast, lung cancer, Kaposi's sarcoma, and used off-label for other malignancies[6][7][8][9]. - **Indoximod** (1-methyl-D-tryptophan) is an immunomodulatory small molecule that acts as an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO), which plays a role in tumor immune evasion by depleting tryptophan in the tumor microenvironment. The rationale for combining these drugs lies in their complementary mechanisms—taxanes directly kill dividing cancer cells by disrupting mitosis while indoximod may enhance anti-tumor immunity by reversing IDO-mediated immunosuppression. This combination has been explored or proposed primarily in clinical research settings for various solid tumors.

Other names

docetaxel and indoximod and paclitaxeldocetaxel plus indoximod plus paclitaxel